The estimated Net Worth of Cristina Larkin is at least $961 Thousand dollars as of 16 December 2020. Ms. Larkin owns over 12,000 units of Spero Therapeutics Inc stock worth over $18,090 and over the last 7 years she sold SPRO stock worth over $0. In addition, she makes $943,289 as Chief Operating Officer and Chief Commercial Officer at Spero Therapeutics Inc.
Sign up
Ms. Larkin SPRO stock SEC Form 4 insiders trading
Cristina has made over 3 trades of the Spero Therapeutics Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently she exercised 12,000 units of SPRO stock worth $70,800 on 16 December 2020.
The largest trade she's ever made was exercising 12,000 units of Spero Therapeutics Inc stock on 16 December 2020 worth over $70,800. On average, Cristina trades about 1,944 units every 126 days since 2017. As of 16 December 2020 she still owns at least 13,500 units of Spero Therapeutics Inc stock.
You can see the complete history of Ms. Larkin stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Cristina Larkin biography
Cristina Larkin serves as Chief Operating Officer and Chief Commercial Officer of the Company. Ms. Larkin had previously served as our Chief Commercial Officer since March 2016. Ms. Larkin has over 24 years of experience developing strategic commercial insights for biopharmaceutical companies and their infectious disease products such as Avycaz, Dalvance, Teflaro, Levaquin and Floxin. Prior to joining us, Ms. Larkin founded CLC Insights, LLC. Prior to that, since 2004, she worked at Actavis, plc, formerly Forest Laboratories, Inc., where she served in various positions, including Assistant Vice President from 2014 to 2015. During that time, Ms. Larkin led the commercial hospital antibiotic franchise team and was responsible for the U.S. launch and execution strategy for several antibiotics. Additionally, she was a member of the business assessments and business development team and played an integral role in several strategic ventures, including the out-licensing of ceftaroline to AstraZeneca plc and the acquisition of Durata. From 1996 to 2002, Ms. Larkin served in various roles at Ortho-McNeil Pharmaceutical, LLC. Ms. Larkin received a bachelor’s degree from Florida State University.
What is the salary of Cristina Larkin?
As the Chief Operating Officer and Chief Commercial Officer of Spero Therapeutics Inc, the total compensation of Cristina Larkin at Spero Therapeutics Inc is $943,289. There are 2 executives at Spero Therapeutics Inc getting paid more, with Ankit Mahadevia having the highest compensation of $1,785,680.
How old is Cristina Larkin?
Cristina Larkin is 49, she's been the Chief Operating Officer and Chief Commercial Officer of Spero Therapeutics Inc since 2017. There are 16 older and 3 younger executives at Spero Therapeutics Inc. The oldest executive at Spero Therapeutics Inc is Dr. David A. Melnick M.D., 69, who is the Chief Medical Officer.
What's Cristina Larkin's mailing address?
Cristina's mailing address filed with the SEC is C/O SPERO THERAPEUTICS, INC., 675 MASSACHUSETTS AVENUE, 14TH FLOOR, CAMBRIDGE, MA, 02139.
Insiders trading at Spero Therapeutics Inc
Over the last 15 years, insiders at Spero Therapeutics Inc have traded over $15,920,732 worth of Spero Therapeutics Inc stock and bought 3,223,281 units worth $44,767,755 . The most active insiders traders include Plc Gsk, Jean Francois Formela, and Capital Management, Llc Aqu.... On average, Spero Therapeutics Inc executives and independent directors trade stock every 71 days with the average trade being worth of $122,858. The most recent stock trade was executed by Ankit Mahadevia on 27 August 2024, trading 5,912 units of SPRO stock currently worth $7,981.
What does Spero Therapeutics Inc do?
spero therapeutics is focused on the development of novel therapies to treat highly resistant bacterial infections. the culture at spero is one of respect, action, collaboration and transparency. spero team members are leaders in the field, and have the ability and desire to be a part of a team. at spero, a feeling that we are part of something groundbreaking and innovative fuels our approach.
What does Spero Therapeutics Inc's logo look like?
Complete history of Ms. Larkin stock trades at Spero Therapeutics Inc
Spero Therapeutics Inc executives and stock owners
Spero Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Ankit Mahadevia,
President, Chief Executive Officer, Director -
Dr. Ankit Mahadevia M.D., MBA,
Co-Founder, CEO, Pres & Director -
Cristina Larkin,
Chief Operating Officer and Chief Commercial Officer -
David Melnick,
Cheif Medical Officer -
Dr. David A. Melnick M.D.,
Chief Medical Officer -
Cristina Larkin,
Chief Operating Officer -
Thomas Parr,
Chief Scientific Officer -
Cynthia Smith,
Independent Director -
Milind Deshpande,
Independent Chairman of the Board -
Frank Thomas,
Independent Director -
Patrick Vink,
Independent Director -
John Pottage,
Independent Director -
Jean-Francois Formela,
Independent Director -
Sharon Klahre,
IR Contact Officer -
Scott Jackson,
Independent Director -
Timothy Keutzer,
Chief Development Officer -
Stephen DiPalma,
Chief Financial Officer, Treasurer -
Timothy Keutzer,
Chief Devel. Officer -
James P. Brady,
Chief Human Resource Officer -
David Musselman,
Sr. VP of Sales & Market Access -
Tamara Lynn Joseph L.L.M., J.D.,
Chief Legal Officer -
Ted Jenkins,
VP & Head of Investor Relations -
Dr. Thomas R. Parr Jr., Ph.D.,
Chief Scientific Officer -
Satyavrat Shukla C.F.A.,
Chief Financial Officer -
David P Southwell,
Director -
John J Gorman,
Director -
Jack Fingerhut,
President -
Allen S Greene,
Chairman of the Board and CEO -
Lager H Martin,
Director -
Joel Sendek,
Chief Financial Officer -
Plc Gsk,
10% owner -
Joseph R Fish,
EVP & Chief Technology Officer -
Leonard J Stanley,
Director -
Vikas Goyal,
Director -
Casper Breum,
Director -
Stanley P Wirtheim,
Chief Financial Officer -
Zohar Ben Dov,
10% owner -
Esther Rajavelu,
See Remarks -
Capital Management, Llc Aqu...,
-
Kathleen Tregoning,
-
Kamal Hamed,
Chief Medical Officer -
Sath Shukla,
CEO & President -
Tamara L Joseph,
Chief Legal Officer